Cargando…
The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
BACKGROUND: Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed. METHODS: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a randomized placebo-contro...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280687/ https://www.ncbi.nlm.nih.gov/pubmed/14614780 http://dx.doi.org/10.1186/1472-6904-3-4 |
_version_ | 1782121063564443648 |
---|---|
author | Mills, Edward Prousky, Jonathan Raskin, Gannady Gagnier, Joel Rachlis, Beth Montori, Victor M Juurlink, David |
author_facet | Mills, Edward Prousky, Jonathan Raskin, Gannady Gagnier, Joel Rachlis, Beth Montori, Victor M Juurlink, David |
author_sort | Mills, Edward |
collection | PubMed |
description | BACKGROUND: Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed. METHODS: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a randomized placebo-controlled blinded trial of a single dose of an OTC, immediate-release niacin 500 mg (n = 33), or a single dose of placebo (n = 35) on an empty stomach. The outcomes measured were self-reported incidence of flushing and other adverse effects. RESULTS: 33 volunteers on niacin (100%) and 1 volunteer on placebo (3%) flushed (relative risk 35, 95% confidence interval (CI) 6.8–194.7). Mean time to flushing on niacin was 18.2 min (95% CI: 12.7–23.6); mean duration of flushing was 75.4 min (95% CI: 62.5–88.2). Other adverse effects occurred commonly in the niacin group: chills (51.5% vs. 0%, P < .0001), generalized pruritus (75% vs. 0%, P = <.001), gastrointestinal upset (30% vs. 3%, P = .005), and cutaneous tingling (30% vs. 0%, P = <.001). Six participants did not tolerate the adverse effects of niacin and 3 required medical attention. CONCLUSION: Clinicians counseling patients about niacin should alert patients not only about flushing but also about gastrointestinal symptoms, the most severe in this study. They should not trust that patients would receive information about these side effects or their prevention (with aspirin) from the OTC packet insert. |
format | Text |
id | pubmed-280687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-2806872003-12-02 The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] Mills, Edward Prousky, Jonathan Raskin, Gannady Gagnier, Joel Rachlis, Beth Montori, Victor M Juurlink, David BMC Clin Pharmacol Research Article BACKGROUND: Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed. METHODS: 51 female and 17 male healthy volunteers (mean age 27 years SD 4.4) participated in a randomized placebo-controlled blinded trial of a single dose of an OTC, immediate-release niacin 500 mg (n = 33), or a single dose of placebo (n = 35) on an empty stomach. The outcomes measured were self-reported incidence of flushing and other adverse effects. RESULTS: 33 volunteers on niacin (100%) and 1 volunteer on placebo (3%) flushed (relative risk 35, 95% confidence interval (CI) 6.8–194.7). Mean time to flushing on niacin was 18.2 min (95% CI: 12.7–23.6); mean duration of flushing was 75.4 min (95% CI: 62.5–88.2). Other adverse effects occurred commonly in the niacin group: chills (51.5% vs. 0%, P < .0001), generalized pruritus (75% vs. 0%, P = <.001), gastrointestinal upset (30% vs. 3%, P = .005), and cutaneous tingling (30% vs. 0%, P = <.001). Six participants did not tolerate the adverse effects of niacin and 3 required medical attention. CONCLUSION: Clinicians counseling patients about niacin should alert patients not only about flushing but also about gastrointestinal symptoms, the most severe in this study. They should not trust that patients would receive information about these side effects or their prevention (with aspirin) from the OTC packet insert. BioMed Central 2003-11-13 /pmc/articles/PMC280687/ /pubmed/14614780 http://dx.doi.org/10.1186/1472-6904-3-4 Text en Copyright © 2003 Mills et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Mills, Edward Prousky, Jonathan Raskin, Gannady Gagnier, Joel Rachlis, Beth Montori, Victor M Juurlink, David The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] |
title | The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] |
title_full | The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] |
title_fullStr | The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] |
title_full_unstemmed | The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] |
title_short | The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] |
title_sort | safety of over-the-counter niacin. a randomized placebo-controlled trial [isrctn18054903] |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280687/ https://www.ncbi.nlm.nih.gov/pubmed/14614780 http://dx.doi.org/10.1186/1472-6904-3-4 |
work_keys_str_mv | AT millsedward thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT prouskyjonathan thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT raskingannady thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT gagnierjoel thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT rachlisbeth thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT montorivictorm thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT juurlinkdavid thesafetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT millsedward safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT prouskyjonathan safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT raskingannady safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT gagnierjoel safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT rachlisbeth safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT montorivictorm safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 AT juurlinkdavid safetyofoverthecounterniacinarandomizedplacebocontrolledtrialisrctn18054903 |